Malignant Diseases

Updated: July 12, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

cyclophosphamide

intermittent therapy:

40 - 50

mg/kg

Intravenous (IV)

dose/day

2 - 5

days

Dose Adjustments

continuous daily therapy: 60-120 mg/m² IV once a day intermittent therapy: 400-1000 mg/m² orally once a day for 4-5 days continuous daily therapy: 50-100 mg/m² orally once a day

vincristine

1.4

mg/m^2

Intravenous (IV)

over one minute once a week

levamisole

Administer 50 mg as an oral dose three times a day for a duration of three days, commencing between 7 to 30 days after the surgical procedure
Administration of maintenance therapy for one year, involving a 3-day regimen at two-week intervals, could be considered

cyclophosphamide

intermittent therapy:

40 - 50

mg/kg

Intravenous (IV)

2 - 5

days

Dose Adjustments

continuous daily therapy: 60-120 mg/m² IV once a day intermittent therapy: 400-1000 mg/m² orally once a day for 4-5 days continuous daily therapy: 50-100 mg/m² orally once a day

vincristine

The recommended dose for <18 years and <10 kg :

0.05

mg/kg

Intravenous (IV)

over one minute once a week as an initial dose
2 mg/m2 IV given over one minute once a week as the maximum dose
The recommended dose for<18 years and >10 kg: 1-2 mg/m2 IV given over one minute once a week

Future Trends